May 10, 2013 / 12:26 PM / 6 years ago

Eli Lilly's lymphoma drug fails in late-stage trial

May 10 (Reuters) - Eli Lilly and Co said it will stop developing its experimental cancer drug after a late-stage trial failed to show a statistically significant increase in patients’ disease-free survival.

The drug, enzastaurin, was being tested in lymphoma patients who were at high risk of relapse following a chemotherapy treatment. Lymphoma is a cancer of the lymphatic system.

The decision to stop the drug’s development will result in a second-quarter charge of about $30 million but the company’s 2013 forecast remained unchanged, Lilly said in a statement.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below